Clinical Trials Logo

Atrial Fibrillation clinical trials

View clinical trials related to Atrial Fibrillation.

Filter by:

NCT ID: NCT01959425 Terminated - Clinical trials for Paroxysmal Atrial Fibrillation

Oral Anticoagulation Therapy Pilot Study

OAT
Start date: April 17, 2013
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.

NCT ID: NCT01952743 Terminated - Hypertension Clinical Trials

Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

Start date: September 2013
Phase: N/A
Study type: Interventional

We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.

NCT ID: NCT01945229 Terminated - Atrial Fibrillation Clinical Trials

Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)

TAMBOURINE
Start date: February 2014
Phase:
Study type: Observational

Background: Atrial fibrillation is a common heart rhythm disturbance affecting some 1-2% of the western population. It may cause symptoms such as irregular heartbeats, shortness of breath, and fatigue. It may also be asymptomatic (ie "silent atrial fibrillation). In some cases, atrial fibrillation is permanent whereas in others it is sporadic. Regardless of symptoms, there is an increased risk of stroke in some patients with this condition. Novel technologies are being developed to increase detection of silent atrial fibrillation, in order to find patients who might benefit from treatment with oral anticoagulants (blood-thinning medications) in order to reduce the risk of stroke. One of these technologies is thumb-ECG, a simple way for a patient to have his or her heart rhythm reliably analyzed at home. Hyperthyroidism (sometimes referred to as "toxic goiter") is defined as an excessive production of thyroid hormone. It is known that hyperthyroidism may cause atrial fibrillation in about 8% of cases. Objective: To provide thumb-ECG-monitors to hyperthyroid patients before and after treating their hormonal disturbance, in order to find episodes of silent atrial fibrillation. Design: Prospective observational study. Hypotheses: - Primary hypothesis: Silent atrial fibrillation is at least as common as overt atrial fibrillation in hyperthyroid patients. - Secondary hypothesis nr 1: Atrial fibrillation continues to be more prevalent compared to the normal population even after hyperthyroidism is treated. - Secondary hypothesis nr 2: The majority of patients with hyperthyroidism and atrial fibrillation are at increased risk of stroke and should be considered for treatment with oral anticoagulants.

NCT ID: NCT01925885 Terminated - Clinical trials for Paroxysmal Atrial Fibrillation

Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)

FIRMAT-PAF
Start date: September 2013
Phase: N/A
Study type: Interventional

- Hypothesis: Focal Impulse and Rotor Modulation (FIRM) will substantially reduce or eliminate clinical atrial fibrillation in subjects with accepted indications for catheter ablation of paroxysmal AF, compared to standard pulmonary vein isolation. - Summary: This is a prospective randomized study to assess the safety and effectiveness of FIRM procedures only, versus standard Pulmonary Vein Isolation (PVI) procedures for the treatment of symptomatic paroxysmal atrial fibrillation.

NCT ID: NCT01887353 Terminated - Heart Failure Clinical Trials

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

RAD HF
Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.

NCT ID: NCT01868243 Terminated - Primary Disease Clinical Trials

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

DAWA
Start date: August 2013
Phase: Phase 2/Phase 3
Study type: Interventional

DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus. There are no formal primary or secondary clinical efficacy or safety outcomes because it is a pilot study.

NCT ID: NCT01845974 Terminated - Atrial Fibrillation Clinical Trials

Atrial Pressure Electrophysiology Pilot Study

APES
Start date: May 2013
Phase: N/A
Study type: Interventional

This study examined data elements of hemodynamic, electrophysiologic and electrolyte trends comparing 2 different types of catheters used during a procedure to treat medication resistant atrial fibrillation-radiofrequency catheter ablation. A high flow catheter delivers a high volume of saline during the procedure. The low flow catheter delivers a low volume of saline during the procedure. The patient will be consented and randomized to one of the 2 groups using a computer generated randomization chart. Those that are put in the low flow catheter group will be considered the experimental group. All data will be collected before and after the procedure and each patient will act as their own control within each group.

NCT ID: NCT01824394 Terminated - Atrial Fibrillation Clinical Trials

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Start date: April 1, 2013
Phase: Phase 3
Study type: Interventional

To demonstrate safety and effectiveness of nMARQ Catheter System [nMARQ] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).

NCT ID: NCT01805960 Terminated - Atrial Fibrillation Clinical Trials

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

CONVERT-AF
Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF recurrences within 6 months after electrical cardioversion in patients with persistent AF.

NCT ID: NCT01791218 Terminated - Clinical trials for Coronary Artery Disease

Surgical Pulmonary Vein Isolation Efficiency Study

FIN-PVI
Start date: November 2012
Phase: N/A
Study type: Interventional

A substantial proportion of patients undergoing elective coronary artery bypass grafting have a history of paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation has adverse short-and long term postoperative effects. Pulmonary vein isolation (PVI) seems to be effective treatment for paroxysmal atrial fibrillation. PVI can be done concomitantly with coronary artery bypass grafting, aortic valve replacement for aortic stenosis and combination of them. Procedure is well defined and safe. There is a lack of convincing evidence of the effect on postoperative atrial fibrillation burden, quality of life and symptoms especially in correlation with atrial fibrillation paroxysms.